KALVISTA PHARMACEUTICALS INC (KALV) Stock News

NASDAQ:KALV - Nasdaq - US4834971032 - Common Stock - Currency: USD

13.75 +0.18 (+1.33%)

After market: 13.9 +0.15 (+1.09%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

KALV Latest News, Press Relases and Analysis

All

Press Releases

5 days ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks

14 days ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

16 days ago - By: Benzinga - Mentions: CVM AAPL GILT RARE ...

Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session

20 days ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results

21 days ago - By: Yahoo Finance - Mentions: VZ

KalVista price target raised to $37 from $22 at BofA

22 days ago - By: Benzinga - Mentions: KLAC ABT DHR GS ...

Meta Platforms To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Tuesday

23 days ago - By: Investor's Business Daily

KalVista Ends Its Unexpectedly Messy Path To Approval In HAE Treatment

23 days ago - By: Bloomberg

KalVista Shares Surge as FDA Approves New Drug After Delay

23 days ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

a month ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Enters into Licensing Agreement with Pendopharm to Commercialize Sebetralstat for HAE in Canada

a month ago - By: Investor's Business Daily - Mentions: GSK

How KalVista Pharma Is Taking On A Rare But Deadly Disease

a month ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Presents New Data at the European Academy of Allergy and Clinical Immunology Congress 2025 on the Efficacy of Sebetralstat for the On-demand Treatment of HAE Attacks Among Patients Receiving Long-Term Prophylaxis

2 months ago - By: Bloomberg

FDA Tells Drugmaker ‘Heavy Workload’ to Delay Approval Decision

2 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat NDA for Hereditary Angioedema Due to FDA Resource Constraints

2 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals to Present New Sebetralstat Data at the European Academy of Allergy and Clinical Immunology Congress 2025

2 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Medical Congress Presentations Highlight Potential of Sebetralstat to Redefine Hereditary Angioedema Management

2 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

2 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals to Present New Sebetralstat Data With 10 Abstracts Accepted at Upcoming Medical Meetings

3 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference

4 months ago - By: Yahoo Finance - Mentions: TSLA LVO

LiveOne reports preliminary FY25 revenue $112M+, consensus $118.08M

4 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan

4 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference

4 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial

5 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update

5 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals to Host Investor Webcast Highlighting Commercialization Strategy, Plans and Progress for Sebetralstat in Hereditary Angioedema

5 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting